Edwards Lifesciences Continually Innovating Ahead Of Q3 Results, Cardio Portfolio Thrives

Edwards Lifesciences gets a buy for my initial rating. Strengths come from recent FDA approvals, a niche portfolio serving the cardiology segment, and impressive operating margins and operating cash flow. EW's price return vs. key benchmarks showed weakness this year.

Seeking Alpha • 13 hours ago

Is This the Right Time to Hold EW Stock in Your Portfolio?

Edwards Lifesciences' TMTT and TAVR growth, strong clinical evidence and solid balance sheet support expansion, but tariffs and currency headwinds threaten margins.

Zacks Investment Research • Oct 22, 2026

FDA Approval of Edwards Lifesciences' PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy who are deemed at intermediate or greater risk for surgery and deemed appropriate for transcatheter edge-to-edge tr.

Business Wire • Oct 21, 2026

7 healthcare stocks that stand out as investors pay up for the sector

Investors have pushed the healthcare sector to a record high, and some favored stocks have high projected revenue growth rates through 2028.

Market Watch • Oct 21, 2026

Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Lifescie.

Business Wire • Oct 7, 2026

Edwards Lifesciences to Host Investor Event in Conjunction With TCT

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team. A live webcast of the event will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived versio.

Business Wire • Oct 5, 2026

Nike, Synaptics And 3 Stocks To Watch Heading Into Friday

With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Benzinga • Oct 2, 2026

Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement. For many pediatric patients, pulmonary valve replacement is not a one-time event. The AUTUS valve is the first FDA-approved surgical pulmonary valve designed for pediatric anatomy,.

Business Wire • Oct 1, 2026

Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead

Edwards Lifesciences NYSE: EW outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE, SAPIEN M3 and surgical therapies.

MarketBeat • Sep 17, 2026

Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Seeking Alpha • Sep 16, 2026